Friday, December 16, 2016

BRIEF-Adamis Pharmaceuticals announces NDA resubmission of its allergy treatment drug

* Resubmission is intended to address issues raised by FDA

in agency's June 2016 complete response letter

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)